QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:JYNT

Joint (JYNT) Stock Price, News & Analysis

$13.06
+0.29 (+2.27%)
(As of 04:00 PM ET)
Today's Range
$12.68
$13.29
50-Day Range
$9.04
$13.09
52-Week Range
$7.31
$16.92
Volume
63,876 shs
Average Volume
100,488 shs
Market Capitalization
$193.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.50

Joint MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
63.6% Upside
$21.50 Price Target
Short Interest
Healthy
5.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Joint in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
284.62%
From $0.13 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars

Medical Sector

335th out of 939 stocks

Patent Owners & Lessors Industry

3rd out of 6 stocks

JYNT stock logo

About Joint Stock (NASDAQ:JYNT)

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

JYNT Stock Price History

JYNT Stock News Headlines

On Holding Posts Adj. Loss In Q4 - Quick Facts
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Joint Q4 2023 Earnings Preview
Best joint personal loans of February 2024
The Joint Corp (JYNT)
The Joint Corp. Reports 2023 Operating Metrics
How to Get a Joint Personal Loan
Best joint checking accounts of January 2024
Returns Are Gaining Momentum At Joint (NASDAQ:JYNT)
See More Headlines
Receive JYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Patent owners & lessors
Sub-Industry
N/A
Current Symbol
NASDAQ:JYNT
Employees
444
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.50
High Stock Price Target
$30.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+68.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-9,750,000.00
Pretax Margin
1.39%

Debt

Sales & Book Value

Annual Sales
$117.70 million
Cash Flow
$0.74 per share
Book Value
$1.68 per share

Miscellaneous

Free Float
14,185,000
Market Cap
$188.74 million
Optionable
Optionable
Beta
1.57
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Peter D. Holt (Age 65)
    CEO, President & Director
    Comp: $469.55k
  • Jake SingletonJake Singleton (Age 42)
    Chief Financial Officer
    Comp: $280.92k
  • Mr. Jorge Armenteros
    Senior Vice President of Operations
  • Mr. Charles Nelles
    Chief Technology Officer
  • Dr. Steven Knauf
    Vice President of Chiropractic & Compliance
  • Ms. Lori I. Abou Habib (Age 44)
    Chief Marketing Officer
  • Ms. Krischelle Tennessen
    Chief Human Resources Officer
  • Mr. Eric Simon
    Senior VP of Franchise Sales & Development
  • Mr. Craig P. Colmar J.D. (Age 71)
    Secretary
    Comp: $37k

JYNT Stock Analysis - Frequently Asked Questions

Should I buy or sell Joint stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" JYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JYNT, but not buy additional shares or sell existing shares.
View JYNT analyst ratings
or view top-rated stocks.

What is Joint's stock price target for 2024?

3 brokers have issued 1-year price targets for Joint's shares. Their JYNT share price targets range from $13.00 to $30.00. On average, they predict the company's stock price to reach $21.50 in the next year. This suggests a possible upside of 63.6% from the stock's current price.
View analysts price targets for JYNT
or view top-rated stocks among Wall Street analysts.

How have JYNT shares performed in 2024?

Joint's stock was trading at $9.61 at the start of the year. Since then, JYNT stock has increased by 36.7% and is now trading at $13.14.
View the best growth stocks for 2024 here
.

Are investors shorting Joint?

Joint saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 846,900 shares, a decrease of 10.8% from the February 29th total of 949,000 shares. Based on an average daily volume of 99,500 shares, the short-interest ratio is currently 8.5 days.
View Joint's Short Interest
.

When is Joint's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our JYNT earnings forecast
.

How were Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings results on Wednesday, September, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.02. The company had revenue of $29.31 million for the quarter, compared to analyst estimates of $29.85 million. Joint had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 7.80%.

What is Peter D. Holt's approval rating as Joint's CEO?

87 employees have rated Joint Chief Executive Officer Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among the company's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Advanced Micro Devices (AMD), RTX (RTX), Salesforce (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did Joint IPO?

Joint (JYNT) raised $20 million in an initial public offering on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.

Who are Joint's major shareholders?

Joint's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.99%), Vanguard Group Inc. (6.99%), Skylands Capital LLC (4.09%), Dimensional Fund Advisors LP (1.21%), Northern Trust Corp (0.92%) and Russell Investments Group Ltd. (0.56%). Insiders that own company stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel, Peter D Holt and Ronald V Davella.
View institutional ownership trends
.

How do I buy shares of Joint?

Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JYNT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners